IQVIA recognized as a leader in IDC MarketScape’s 2024 assessment for decentralized clinical trial technologies and consulting services
IQVIA (NYSE:IQV) has been recognized as a leader in the IDC MarketScape's 2024 assessment for decentralized clinical trial (DCT) technologies and consulting services. The company's leadership position is attributed to its extensive network of over 200 DCT consultants, comprehensive DCT-enabling technologies, and expertise in regulatory strategy implementation.
IDC's first assessment of DCT technology solutions highlights IQVIA's strengths in:
- Deep clinical and DCT implementation strategy expertise across therapeutic areas
- Healthcare-grade AI implementation across the value chain
- Novel GenAI tools for enhanced patient experience
- Country-wise regulatory strategy expertise
Decentralized clinical trials, which gained momentum during COVID-19, utilize telemedicine and mobile technologies to conduct trial activities remotely. This approach enables patient monitoring through wearable devices and digital tools, reducing the need for in-person site visits.
IQVIA (NYSE:IQV) è stata riconosciuta come leader nella valutazione 2024 di IDC MarketScape per le tecnologie e i servizi di consulenza per le sperimentazioni cliniche decentralizzate (DCT). La posizione di leadership dell'azienda è attribuita alla sua vasta rete di oltre 200 consulenti DCT, alle tecnologie complete che abilitano le DCT e all'esperienza nell'implementazione delle strategie normative.
La prima valutazione di IDC delle soluzioni tecnologiche DCT evidenzia i punti di forza di IQVIA in:
- Profonda esperienza nella strategia di implementazione clinica e DCT in diverse aree terapeutiche
- Implementazione di AI di livello sanitario lungo l'intera catena del valore
- Strumenti GenAI innovativi per migliorare l'esperienza del paziente
- Esperienza nella strategia normativa a livello nazionale
Le sperimentazioni cliniche decentralizzate, che hanno guadagnato slancio durante il COVID-19, utilizzano la telemedicina e le tecnologie mobili per condurre attività di sperimentazione a distanza. Questo approccio consente il monitoraggio dei pazienti tramite dispositivi indossabili e strumenti digitali, riducendo la necessità di visite in loco.
IQVIA (NYSE:IQV) ha sido reconocida como líder en la evaluación 2024 de IDC MarketScape para tecnologías y servicios de consultoría de ensayos clínicos descentralizados (DCT). La posición de liderazgo de la empresa se atribuye a su amplia red de más de 200 consultores DCT, a las tecnologías integrales que habilitan las DCT y a su experiencia en la implementación de estrategias regulatorias.
La primera evaluación de IDC de soluciones tecnológicas DCT destaca las fortalezas de IQVIA en:
- Profunda experiencia en estrategias de implementación clínica y DCT en diversas áreas terapéuticas
- Implementación de IA de grado sanitario a lo largo de la cadena de valor
- Nuevas herramientas GenAI para mejorar la experiencia del paciente
- Experiencia en estrategias regulatorias a nivel nacional
Los ensayos clínicos descentralizados, que ganaron impulso durante el COVID-19, utilizan telemedicina y tecnologías móviles para realizar actividades de ensayo de forma remota. Este enfoque permite el monitoreo de pacientes a través de dispositivos portátiles y herramientas digitales, reduciendo la necesidad de visitas presenciales.
IQVIA (NYSE:IQV)는 분산 임상 시험(DCT) 기술 및 컨설팅 서비스에 대한 IDC MarketScape의 2024 평가에서 리더로 인정받았습니다. 회사의 리더십 위치는 200명 이상의 DCT 컨설턴트로 구성된 광범위한 네트워크, 포괄적인 DCT 지원 기술 및 규제 전략 구현 전문성에 기인합니다.
IDC의 DCT 기술 솔루션에 대한 첫 번째 평가는 IQVIA의 강점을 다음과 같이 강조합니다:
- 치료 영역 전반에 걸친 깊이 있는 임상 및 DCT 구현 전략 전문성
- 가치 사슬 전반에 걸친 의료 수준의 AI 구현
- 환자 경험 향상을 위한 새로운 GenAI 도구
- 국가별 규제 전략 전문성
COVID-19 동안 활기를 띠었던 분산 임상 시험은 원격으로 시험 활동을 수행하기 위해 원격 의료 및 모바일 기술을 활용합니다. 이 접근 방식은 웨어러블 장치와 디지털 도구를 통해 환자를 모니터링할 수 있게 하여 대면 방문의 필요성을 줄입니다.
IQVIA (NYSE:IQV) a été reconnue comme un leader dans l'évaluation 2024 d'IDC MarketScape pour les technologies et services de conseil en essais cliniques décentralisés (DCT). La position de leadership de l'entreprise est attribuée à son vaste réseau de plus de 200 consultants DCT, à ses technologies complètes permettant les DCT et à son expertise dans la mise en œuvre de stratégies réglementaires.
La première évaluation d'IDC des solutions technologiques DCT met en évidence les forces d'IQVIA dans:
- Une expertise approfondie en stratégie d'implémentation clinique et DCT dans divers domaines thérapeutiques
- Mise en œuvre d'IA de niveau santé tout au long de la chaîne de valeur
- Nouveaux outils GenAI pour améliorer l'expérience patient
- Expertise en stratégie réglementaire par pays
Les essais cliniques décentralisés, qui ont gagné en importance pendant le COVID-19, utilisent la télémédecine et les technologies mobiles pour réaliser des activités d'essai à distance. Cette approche permet le suivi des patients via des dispositifs portables et des outils numériques, réduisant ainsi le besoin de visites sur site.
IQVIA (NYSE:IQV) wurde als führendes Unternehmen in der IDC MarketScape-Bewertung 2024 für dezentrale klinische Studien (DCT) Technologien und Beratungsdienste anerkannt. Die Führungsposition des Unternehmens wird seiner umfangreichen Netzwerk von über 200 DCT-Beratern, umfassenden DCT-fähigen Technologien und Expertise in der Umsetzung regulatorischer Strategien zugeschrieben.
Die erste Bewertung von IDC zu DCT-Technologielösungen hebt die Stärken von IQVIA hervor:
- Tiefe klinische und DCT-Implementierungsstrategie-Expertise in verschiedenen therapeutischen Bereichen
- Implementierung von KI auf Gesundheitsniveau entlang der gesamten Wertschöpfungskette
- Neue GenAI-Tools zur Verbesserung der Patientenerfahrung
- Expertise in der regulatorischen Strategie nach Ländern
Dezentrale klinische Studien, die während COVID-19 an Bedeutung gewannen, nutzen Telemedizin und mobile Technologien, um Studienaktivitäten aus der Ferne durchzuführen. Dieser Ansatz ermöglicht die Patientenüberwachung über tragbare Geräte und digitale Werkzeuge, wodurch die Notwendigkeit von persönlichen Besuchen vor Ort verringert wird.
- None.
- None.
IDC, a global provider of market intelligence, says in its report: “Consider IQVIA when seeking deep clinical and DCT implementation strategy expertise across therapeutics areas and phases, with over 200 DCT consultants, a wide portfolio of DCT-enabling technologies and services, and expertise in providing inputs on country-wise regulatory strategy for DCT implementation and on business process transformation for implementing a DCT model, as well as a focus on implementing healthcare-grade AI across the value chain, with novel GenAI tools to transform patient experience.”
“Call them what you may — decentralized trials, virtual trials, hybrid trials — DCTs are here to stay,” wrote Dr. Nimita Limaye, IDC’s research VP, Life Sciences R&D Strategy and Technology. “The focus is on integration, integration of technologies, integration of touch points to create unified and meaningful experiences, and the alignment of technologies and operating models. The way the industry is perceiving DCTs is maturing. No, DCTs aren’t going away. Instead, DCTs are becoming a 'business as usual' strategy today.”
Decentralized clinical trials, which gained popularity during the COVID-19 pandemic, are clinical trial studies that use telemedicine and mobile technologies to perform trial activities outside of a traditional clinical site. For example, patients can be monitored remotely using wearable devices, and the use of digital tools to communicate and collect data means patients are required to make fewer visits to trial sites.
IQVIA’s integrated strategy helps customers adopt, run and execute decentralized trial approaches, delivering a unique and differentiating experience.
"At IQVIA, we are proud to be a leader in decentralized clinical trials and remain focused on delivering cutting-edge technology solutions that enhance patient and site experiences and drive healthcare forward,” said Susan Hill, senior vice president, product management, Digital Products & Solutions at IQVIA.
"Being named a Leader in the IDC MarketScape report highlights our commitment to revolutionizing clinical trials through innovation and excellence. We are honored to receive this distinction and empower our customers to achieve outstanding results," said Alison Liddy, senior vice president for Patient and Site Centric Solutions at IQVIA.
This report is IDC’s first assessment of both DCT technology solutions and consulting services in life science R&D. The firm evaluated vendors’ capabilities, strategies and market success factors. Read the 2024 IDC MarketScape excerpt here.
About IQVIA
IQVIA (NYSE:IQV) is a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries. IQVIA’s portfolio of solutions are powered by IQVIA Connected Intelligence™ to deliver actionable insights and services built on high-quality health data, Healthcare-grade AI™, advanced analytics, the latest technologies and extensive domain expertise. IQVIA is committed to using AI responsibly, with AI-powered capabilities built on best-in-class approaches to privacy, regulatory compliance and patient safety, and delivering AI to the high standards of trust, scalability and precision demanded by the industry. With approximately 88,000 employees in over 100 countries, including experts in healthcare, life sciences, data science, technology and operational excellence, IQVIA is dedicated to accelerating the development and commercialization of innovative medical treatments to help improve patient outcomes and population health worldwide.
IQVIA is a global leader in protecting individual patient privacy. The company uses a wide variety of privacy-enhancing technologies and safeguards to protect individual privacy while generating and analyzing information on a scale that helps healthcare stakeholders identify disease patterns and correlate with the precise treatment path and therapy needed for better outcomes. IQVIA’s insights and execution capabilities help biotech, medical device and pharmaceutical companies, medical researchers, government agencies, payers and other healthcare stakeholders tap into a deeper understanding of diseases, human behaviors and scientific advances, in an effort to advance their path toward cures. To learn more, visit www.iqvia.com.
About IDC MarketScape:
IDC MarketScape vendor assessment model is designed to provide an overview of the competitive fitness of technology and service suppliers in a given market. The research utilizes a rigorous scoring methodology based on both qualitative and quantitative criteria that results in a single graphical illustration of each supplier’s position within a given market. IDC MarketScape provides a clear framework in which the product and service offerings, capabilities and strategies, and current and future market success factors of technology suppliers can be meaningfully compared. The framework also provides technology buyers with a 360-degree assessment of the strengths and weaknesses of current and prospective suppliers.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250310714233/en/
Kerri Joseph, IQVIA Investor Relations (kerri.joseph@iqvia.com)
+1.973.541.3558
Alissa Maupin, IQVIA Media Relations (alissa.maupin1@iqvia.com)
+1.919.923.6785
Source: IQVIA
FAQ
What recognition did IQVIA receive in IDC MarketScape's 2024 assessment?
How many DCT consultants does IQVIA (IQV) have in their network?
What are the key features of IQVIA's decentralized clinical trials?
What technological advantages does IQVIA (IQV) offer in their DCT solutions?
How does IQVIA's DCT approach benefit clinical trial participants?
